Carotuximab
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2].
Product Specifications
Product Name Alternative
TRC105; DE-122
UNSPSC
12352203
Target
TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/carotuximab.html
Purity
95.0
Solubility
10 mM in DMSO
Smiles
[Carotuximab]
Molecular Weight
(144.8 kDa)
References & Citations
[1]Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne) . 2022 Sep 7;9:845918.|[2]June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6 (10) :e05242.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99494/Carotuximab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99494/Carotuximab-SDS-MedChemExpress.pdf
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
CAS Number
[1268714-50-6]
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
